Idiopathic Short Stature - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 36 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Idiopathic Short Stature - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Idiopathic Short Stature - Pipeline Review, H2 2014', provides an overview of the Idiopathic Short Stature's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Short Stature, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Short Stature and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Short Stature
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Idiopathic Short Stature and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Idiopathic Short Stature products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Short Stature pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Short Stature
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Short Stature pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Idiopathic Short Stature Overview 6
Therapeutics Development 7
Pipeline Products for Idiopathic Short Stature - Overview 7
Pipeline Products for Idiopathic Short Stature - Comparative Analysis 8
Idiopathic Short Stature - Therapeutics under Development by Companies 9
Idiopathic Short Stature - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Idiopathic Short Stature - Products under Development by Companies 13
Idiopathic Short Stature - Companies Involved in Therapeutics Development 14
Bolder Biotechnology, Inc. 14
Braasch Biotech LLC 15
Dong-A Socio Group 16
LG Life Sciences, Ltd. 17
Myungmoon pharmaceutical Co.,Ltd. 18
Idiopathic Short Stature - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 26
BBT-031 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MM-P02-01 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
somatropin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
somatropin SR - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Vaccine for Growth Hormone Deficiencies - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Idiopathic Short Stature - Recent Pipeline Updates 32
Idiopathic Short Stature - Dormant Projects 33
Idiopathic Short Stature - Discontinued Products 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products under Development for Idiopathic Short Stature, H2 2014 7
Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Idiopathic Short Stature - Pipeline by Bolder Biotechnology, Inc., H2 2014 14
Idiopathic Short Stature - Pipeline by Braasch Biotech LLC, H2 2014 15
Idiopathic Short Stature - Pipeline by Dong-A Socio Group, H2 2014 16
Idiopathic Short Stature - Pipeline by LG Life Sciences, Ltd., H2 2014 17
Idiopathic Short Stature - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Idiopathic Short Stature Therapeutics - Recent Pipeline Updates, H2 2014 32
Idiopathic Short Stature - Dormant Projects, H2 2014 33
Idiopathic Short Stature - Discontinued Products, H2 2014 34